Aurora Cannabis Applauds Germany's Historic Cannabis Legalization

The Anticipated De-scheduling of Cannabis to Drive Growth in Germany's Medical Cannabis Market

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), a prominent global medical cannabis company based in Canada, commends the German government's recent approval of cannabis legalization, marking a significant advancement in improving patient access to medical cannabis with the formal enactment of the Cannabis Act.

The Germany Reform

This reform represents a much-needed shift towards a more accessible medical cannabis market and a renewed commitment to patient care. Following in the footsteps of progressive nations like Canada, Germany's move sets a standard for global expansion.

Dirk Heitepriem, Vice President of External Affairs at Aurora Europe, GmbH, expressed, "Germany's reform represents a major step forward in patient access to medical cannabis and a more liberal approach to cannabis, which we have long advocated for. With cannabis de-scheduling, more patients will have access to treatment, reinforcing our commitment to patient outreach and ensuring comprehensive access to high-quality medical cannabis. Today's enhanced access reaffirms our dedication to driving progressive change."

In addition to the cultural significance of Germany's strides in cannabis legalization, these developments present a unique opportunity for Aurora, a leading supplier of medical cannabis in Germany, to further expand its presence in the country.

The reclassification of cannabis as a non-narcotic substance is expected to encourage more patients to engage with their healthcare providers regarding medical cannabis, facilitating increased access, education, and awareness about its benefits. Aurora extends its congratulations to the German government on the successful passage of cannabis law reforms that aim to enhance patient care.

For more information about medical cannabis products, healthcare professionals can reach out to Aurora Medical.

About Aurora

Aurora is pioneering the cannabis industry globally, serving both medical and consumer markets across Canada, Europe, Australia, and South America. Headquartered in Edmonton, Alberta, Aurora is committed to improving people's lives through cannabis. The company's portfolio includes a range of adult-use and medical cannabis brands, reflecting its dedication to quality and innovation. With a focus on science and innovation, Aurora continues to lead the way in the medical, wellness, and recreational cannabis markets worldwide.

Aurora Europe, based in Berlin, Germany, is a subsidiary of Aurora Cannabis Inc., a global leader in the cannabis industry. Dedicated to serving both medical and consumer markets, Aurora Europe provides high-quality medical cannabis products to patients across Europe. As one of the largest authorized importers and distributors of medical cannabis in the European Union and the UK, Aurora Deutschland, a part of Aurora Europe GmbH, is licensed to cultivate medicinal cannabis in Germany. Since May 2022, Aurora Produktions GmbH has been producing one ton of medicinal cannabis annually in Leuna, Saxony-Anhalt. Through its network of EU GMP facilities, Aurora delivers premium medical cannabis to patients worldwide.